2025
Portal and Hepatic Vein Embolization vs Portal Venous Embolization Alone in Cirrhotic and Non-cirrhotic Swine: A Pilot Study
Tefera J, Kuhn T, Matuschewski N, Meister E, Nguyenová J, Kao T, Mutonga M, Bitar R, Kahl V, Zhang X, Shewarega A, Chapiro J, Madoff D. Portal and Hepatic Vein Embolization vs Portal Venous Embolization Alone in Cirrhotic and Non-cirrhotic Swine: A Pilot Study. Journal Of Vascular And Interventional Radiology 2025 PMID: 40043833, DOI: 10.1016/j.jvir.2025.02.028.Peer-Reviewed Original ResearchPost-embolizationCirrhotic groupPortal venous embolizationHepatic vein embolizationPortal venous phaseNon-cirrhotic groupStudent's t-testFLR hypertrophyFLR increaseVein embolizationVenous phaseEffects of PVELiver volumeCT scanVenous embolizationEmbolizationCirrhotic liverFour-week intervalsWeeksT-testFLRLiverPilot studyYorkshire pigsPVEDeuterium MRS for In Vivo Measurement of Lipogenesis in the Liver
Gursan A, de Graaf R, Thomas M, Prompers J, De Feyter H. Deuterium MRS for In Vivo Measurement of Lipogenesis in the Liver. NMR In Biomedicine 2025, 38: e70014. PMID: 39994887, DOI: 10.1002/nbm.70014.Peer-Reviewed Original ResearchConceptsH-MRSHepatic DNLMRS dataLiver tissueMeasurement of lipogenesisDietary interventionLiver lipidsHepatic de novo lipogenesisLow density lipoproteinDetection of deuteriumGold standard measureMetabolic diseasesIncreased hepatic DNLLiverDensity lipoproteinDrinking waterDeuterium labelingIn vivo measurementsNMR dataExcised liver tissueTissueDeuteriumMRSMethylene resonancesDeuterated waterThe evolving role of liver biopsy: Current applications and future prospects
Gopal P, Hu X, Robert M, Zhang X. The evolving role of liver biopsy: Current applications and future prospects. Hepatology Communications 2025, 9: e0628. PMID: 39774070, PMCID: PMC11717517, DOI: 10.1097/hc9.0000000000000628.Peer-Reviewed Original Research
2024
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
Do A, Zahrawi F, Mehal W. Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH). Nature Reviews Drug Discovery 2024, 24: 171-189. PMID: 39609545, DOI: 10.1038/s41573-024-01084-2.Peer-Reviewed Original ResearchSide effect profileTrial end pointsCombination of therapeuticsReverse many aspectsFatty acid synthase inhibitorGenetic susceptibility factorsPlacebo responseEffect profileFibrosis reversalTreated patientsClinical studiesLiver inflammationSynthase inhibitorLiver diseaseTherapeutic approachesClinical useEnd pointsSteatotic liver diseaseTherapeutic landscapeMetabolic environmentHepatocyte deathSusceptibility factorsChronic overnutritionGlobal epidemicLiverWilson Disease: Novel Diagnostic and Therapeutic Approaches
Mariño Z, Schilsky M. Wilson Disease: Novel Diagnostic and Therapeutic Approaches. Seminars In Liver Disease 2024 PMID: 39496313, DOI: 10.1055/a-2460-8999.Peer-Reviewed Original ResearchWilson's diseaseTrials of gene therapyLiver biopsy specimensDried blood spotsCase of WDBiliary copper excretionBiopsy specimensGene therapyDiagnostic advancesMonitoring therapyWD diagnosisNewborn screeningLiver diseaseCopper excretionTherapeutic approachesBlood spotsTherapyTherapeutic objectivesDiseaseDiagnosisLiverCopper assayPatientsExcretionAutosomal Dominant Polycystic Kidney Disease
Suarez M, Titan S, Dahl N. Autosomal Dominant Polycystic Kidney Disease. Advances In Kidney Disease And Health 2024, 31: 496-503. PMID: 39577883, DOI: 10.1053/j.akdh.2024.07.003.Peer-Reviewed Original ResearchConceptsAutosomal dominant polycystic kidney diseaseDelivery of personalized treatmentKidney diseaseKidney failureMinority of patientsDominant polycystic kidney diseaseEnd-stage kidney diseaseRisk of kidney failureCause of end-stage kidney diseasePolycystic kidney diseaseBlood pressure managementMassive hepatomegalySevere complicationsPolycystic liverIntracranial aneurysmsPersonalized treatmentNatural historyOrgan systemsDiseaseTreatmentKidneyPressure managementLiverSystem conditionsPreimplantationResidual Ultrasound-Enhancing Agents Mimicking Portal Venous Gas
Bitar R, Langdon J, Kaur M, Crandall I, McNamara R, Revzin M. Residual Ultrasound-Enhancing Agents Mimicking Portal Venous Gas. Ultrasound Quarterly 2024, 40: e00694. PMID: 39466239, DOI: 10.1097/ruq.0000000000000694.Peer-Reviewed Original ResearchConceptsUltrasound enhancing agentsPortal venous gasBowel ischemiaAbdominal ultrasoundVenous gasEchogenic fociContrast-enhanced echocardiographyEvaluation of cardiac functionPortal venous systemSeries of casesSonographic detectionCardiac functionDifferential diagnosisPortal veinVenous systemObservational studyLiver parenchymaPortal triadsVascular patencyBowelIschemiaEchocardiographyLiverUltrasoundHighlights of Enhanced Recovery After Surgery (ERAS) Programs for Liver Transplantation
Guzzi J, Strand E, Hussain N, Batra R, Deshpande R. Highlights of Enhanced Recovery After Surgery (ERAS) Programs for Liver Transplantation. Current Transplantation Reports 2024, 11: 125-130. DOI: 10.1007/s40472-024-00442-8.Peer-Reviewed Original ResearchOutcomes of repeat conventional transarterial chemoembolization in patients with liver metastases
Ghabili K, Windham-Herman A, Konstantinidis M, Murali N, Borde T, Adam L, Laage-Gaupp F, Lin M, Chapiro J, Georgiades C, Nezami N. Outcomes of repeat conventional transarterial chemoembolization in patients with liver metastases. Annals Of Hepatology 2024, 29: 101529. PMID: 39033928, PMCID: PMC11558520, DOI: 10.1016/j.aohep.2024.101529.Peer-Reviewed Original ResearchConventional transarterial chemoembolizationLiver metastasesNeuroendocrine tumorsColorectal carcinomaTransarterial chemoembolizationOverall survivalLung cancerAssociated with improved patient survivalManagement of liver metastasesMetastatic liver lesionsSingle-institution analysisNonresponding patientsSurvival outcomesPatient survivalResponse assessmentTarget lesionsMetastasisLiver lesionsPatientsResponse rateChemoembolizationSurvivalLiverLesionsCancerFactor VIII Levels and ISTH Disseminated Intravascular Coagulation Scores Do Not Distinguish Disseminated Intravascular Coagulation from the Coagulopathy of Liver Disease
Allen C, Heskel M, Butt A, Tormey C, Pine A, Lee A, Gautam S. Factor VIII Levels and ISTH Disseminated Intravascular Coagulation Scores Do Not Distinguish Disseminated Intravascular Coagulation from the Coagulopathy of Liver Disease. Acta Haematologica 2024, 148: 220-225. PMID: 39004080, DOI: 10.1159/000540239.Peer-Reviewed Original ResearchISTH DIC scoreFactor VIII levelsArea under the curveDIC scoreLiver diseaseFactor VIIIRetrospective chart review of patientsChart review of patientsCoagulopathy of liver diseaseReview of patientsRetrospective chart reviewCalculate area under the curveReceiver operating characteristic curveMultiple logistic regressionISTH scoreLaboratory parametersClinical challengeClinical utilityPatientsCharacteristic curveLab variablesLogistic regressionLiverDiseaseDiagnostic toolGlycolysis in hepatic stellate cells coordinates fibrogenic extracellular vesicle release spatially to amplify liver fibrosis
Khanal S, Liu Y, Bamidele A, Wixom A, Washington A, Jalan-Sakrikar N, Cooper S, Vuckovic I, Zhang S, Zhong J, Johnson K, Charlesworth M, Kim I, Yeon Y, Yoon S, Noh Y, Meroueh C, Timbilla A, Yaqoob U, Gao J, Kim Y, Lucien F, Huebert R, Hay N, Simons M, Shah V, Kostallari E. Glycolysis in hepatic stellate cells coordinates fibrogenic extracellular vesicle release spatially to amplify liver fibrosis. Science Advances 2024, 10: eadn5228. PMID: 38941469, PMCID: PMC11212729, DOI: 10.1126/sciadv.adn5228.Peer-Reviewed Original ResearchConceptsHepatic stellate cellsLiver fibrosisExtracellular vesiclesEV releaseHistone 3 lysine 9 acetylationExtracellular vesicle releaseIncreased EV releaseFibrotic gene expressionNanosized extracellular vesiclesPromoter regionVesicle releasePotential therapeutic targetGene expressionGenetic inhibitionSpatial transcriptomicsStellate cellsGlycolysisUp-regulatedFibrosisTherapeutic targetPericentral zoneLiverPathwayAmplificationExpressionUnderstanding nanoparticle-liver interactions in nanomedicine
He Y, Wang Y, Wang L, Jiang W, Wilhelm S. Understanding nanoparticle-liver interactions in nanomedicine. Expert Opinion On Drug Delivery 2024, 21: 829-843. PMID: 38946471, PMCID: PMC11281865, DOI: 10.1080/17425247.2024.2375400.Peer-Reviewed Original ResearchConceptsLiver Kupffer cellsNanoparticle physicochemical propertiesEnhanced delivery efficiencyAdministered nanoparticlesEffective nanomedicinesKupffer cellsLiver diseasePhagocytic functionClinical translationHepatic diseaseLiver accumulationClinical applicationNanomedicineDelivery efficiencyLiverPhagocytic roleDiseaseLiver and Kidney Transplantation in Elderly Patients
Guzzi J, Strand E, Ozturk B, Agarkov D, Deshpande R. Liver and Kidney Transplantation in Elderly Patients. Transplantology 2024, 5: 98-109. DOI: 10.3390/transplantology5020010.Peer-Reviewed Original ResearchDeep Learning-Based Detect-Then-Track Pipeline for Treatment Outcome Assessments in Immunotherapy-Treated Liver Cancer
Zhou J, Xia Y, Xun X, Yu Z. Deep Learning-Based Detect-Then-Track Pipeline for Treatment Outcome Assessments in Immunotherapy-Treated Liver Cancer. Journal Of Imaging Informatics In Medicine 2024, 38: 380-393. PMID: 38740661, PMCID: PMC11811366, DOI: 10.1007/s10278-024-01132-8.Peer-Reviewed Original ResearchImage-guided percutaneous strategies to improve the resectability of HCC: Portal vein embolization, liver venous deprivation, or radiation lobectomy?
Chan S, Cornman-Homonoff J, Lucatelli P, Madoff D. Image-guided percutaneous strategies to improve the resectability of HCC: Portal vein embolization, liver venous deprivation, or radiation lobectomy? Clinical Imaging 2024, 111: 110185. PMID: 38781614, DOI: 10.1016/j.clinimag.2024.110185.Peer-Reviewed Original ResearchLiver venous deprivationPortal vein embolizationRadiation lobectomyVein embolizationResection of HCCMinimally invasive techniquesStandard of careHepatic malignanciesLiver remnantLiver insufficiencySurgical candidacySurgical techniqueHepatocellular carcinomaInvasive techniquesHepatic functionPercutaneous strategiesResectionPatient's likelihoodLobectomyEmbolizationLiverPatientsFLRCarcinomaMalignancyArtificial intelligence–aided steatosis assessment in donor livers according to the Banff consensus recommendations
Jiao J, Tang H, Sun N, Zhang X. Artificial intelligence–aided steatosis assessment in donor livers according to the Banff consensus recommendations. American Journal Of Clinical Pathology 2024, 162: 401-407. PMID: 38716796, DOI: 10.1093/ajcp/aqae053.Peer-Reviewed Original ResearchBanff Working GroupLiver Allograft PathologyBiopsy specimensDonor liversAllograft pathologyAssociated with primary graft dysfunctionMacrovesicular steatosisPrimary graft dysfunctionManual quantificationSteatosis assessmentLiver biopsy specimensSevere macrovesicular steatosisAssessment of liver steatosisGraft dysfunctionPathological evaluationModerate steatosisEvaluate steatosisConsensus recommendationsLiver steatosisSteatosisBanffLiverPathologyAI modelsArtificial intelligenceArtificial intelligence in liver cancer — new tools for research and patient management
Calderaro J, Žigutytė L, Truhn D, Jaffe A, Kather J. Artificial intelligence in liver cancer — new tools for research and patient management. Nature Reviews Gastroenterology & Hepatology 2024, 21: 585-599. PMID: 38627537, DOI: 10.1038/s41575-024-00919-y.Peer-Reviewed Original ResearchLiver cancer managementLiver cancerCancer managementCancer careArtificial intelligenceClinically approved productsInterdisciplinary trainingTumor typesClinical dataClinical trialsPatient managementClinical useCancerPotential of AILiverHidden informationNatural languageIncorporation of AIAI approachesAI systemsPatientsChapter 13 Liver Sinusoidal Cells in alcohol-associated liver disease
Iwakiri Y. Chapter 13 Liver Sinusoidal Cells in alcohol-associated liver disease. 2024, 285-291. DOI: 10.1016/b978-0-323-95262-0.00013-9.Peer-Reviewed Original ResearchAlcohol-associated liver diseaseLiver sinusoidal endothelial cellsPathogenesis of alcohol-associated liver diseaseChronic alcohol consumptionSinusoidal endothelial cellsLiver diseaseNormal function of immune cellsEndothelial cellsFunction of immune cellsSinusoidal cellsAlcohol consumptionIntrahepatic vascular toneHepatic stellate cellsEndothelial cell populationLiver sinusoidal cellsLiver cell typesImmune cellsAntigen clearanceVascular toneKupffer cells/macrophagesKupffer cellsStellate cellsCell populationsLiver homeostasisLiverFuel oxygenates
Abu-Bakar A, Vasiliou V, Popovic Z, Inayat-Hussain S. Fuel oxygenates. 2024, 859-874. DOI: 10.1016/b978-0-12-824315-2.00736-3.Peer-Reviewed Original ResearchCentral nervous systemChronic progressive nephropathyRat kidney tumorsOccupational health hazardsNon-toxic dosesProgressive nephropathyRisk factorsKidney tumorsInhalation toxicityNervous systemEye irritationWeight gainToxicology studiesReversible effectHealth hazardsRecent seriesHuman odourNephropathyTumorsKidneyRatsDiseaseMiceLiverDosesTreatment of alcohol use disorder in patients with alcohol-associated liver disease: Innovative approaches and a call to action
Haque L, Zuluaga P, Muga R, Fuster D. Treatment of alcohol use disorder in patients with alcohol-associated liver disease: Innovative approaches and a call to action. Addiction Science & Clinical Practice 2024, 19: 19. PMID: 38504384, PMCID: PMC10949674, DOI: 10.1186/s13722-024-00448-8.Peer-Reviewed Original ResearchConceptsAlcohol-associated liver diseaseAlcohol use disorderLiver diseasePresence of liver cirrhosisTreatment of alcohol use disordersUse disorderInnovative treatment strategiesUnhealthy alcohol usePharmacologic treatment choicesTreating unhealthy alcohol useLiver transplantationLiver cirrhosisTreatment strategiesTreatment choiceEfficacious treatmentLiver deathsPatientsAlcohol useDiseaseLiverTreatmentDisordersCirrhosisTransplantation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply